Clinical Trials
5
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2017
Completed
3
60.0%
Recruiting
1
20.0%
Withdrawn
1
20.0%
No approval data available
- TheraCryf received a Korean patent grant for its Orexin-1R antagonist in addiction, completing broad intellectual property coverage across major commercial markets including the US and EU. - The company achieved its first manufacturing milestone ahead of schedule, successfully scaling up production from gram quantities to 0.5kg and initiating 2kg human-grade material manufacturing. - An optimal formulation using Amorphous Solid Dispersions has been identified, enabling a straightforward drug-in-capsule approach for first-in-human studies with enhanced oral absorption. - The company confirmed selection of a non-rodent species for 28-day toxicity studies scheduled to commence in early 2026, supporting clinical trial applications.
- Geneva-based Stalicla SA closed a CHF 2 million financing round led by Addex Therapeutics to sustain operations and advance its precision medicine programs for neurodevelopmental disorders. - The funding supports Stalicla's DEPI precision neuro platform and autism-focused assets STP1 and STP2, while the company prepares for Phase 2 trials targeting specific autism subpopulations. - Stalicla's STP7 (mavoglurant) program, the most clinically advanced mGluR5 negative allosteric modulator, continues toward Phase 3 trials with full NIH-NIDA funding. - Tim Dyer, CEO of Addex Therapeutics, has been appointed Chairman of Stalicla's Board of Directors as part of the financing agreement.
